MAPK1 and endometrial cancer: Tamoxifen has been associated with endometrial cancer proliferative effects and lymph node metastases in users, and this proliferative impact is driven by the GPER/EFGR/ERK/cyclin D1 pathway, which might be blocked by GPER silencing [172].